1. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142(25):e558–e631. PMID:
33215931.
2. Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, et al. Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022; 79(17):1647–1655. PMID:
35483751.
3. Arévalos V, Rodríguez-Arias JJ, Brugaletta S, Micari A, Costa F, Freixa X, et al. Alcohol septal ablation: an option on the rise in hypertrophic obstructive cardiomyopathy. J Clin Med. 2021; 10(11):2276. PMID:
34073940.
4. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013; 381(9862):242–255. PMID:
22874472.
5. Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019; 170(11):741–748. PMID:
31035291.